Skip to main content


We’d like to understand how you use our websites in order to improve them. Register your interest.

Transplanted human fecal microbiota enhanced Guillain Barré syndrome autoantibody responses after Campylobacter jejuni infection in C57BL/6 mice



Campylobacter jejuni is the leading antecedent infection to the autoimmune neuropathy Guillain-Barré syndrome (GBS), which is accompanied by an autoimmune anti-ganglioside antibody attack on peripheral nerves. Previously, we showed that contrasting immune responses mediate C. jejuni induced colitis and autoimmunity in interleukin-10 (IL-10)-deficient mice, dependent upon the infecting strain. Strains from colitis patients elicited T helper 1 (TH1)-dependent inflammatory responses while strains from GBS patients elicited TH2-dependent autoantibody production. Both syndromes were exacerbated by antibiotic depletion of the microbiota, but other factors controlling susceptibility to GBS are unknown.


Using 16S rRNA gene high-throughput sequencing, we examined whether structure of the gut microbial community alters host (1) gastrointestinal inflammation or (2) anti-ganglioside antibody responses after infection with C. jejuni strains from colitis or GBS patients. We compared these responses in C57BL/6 mice with either (1) stable human gut microbiota (Humicrobiota) transplants or (2) conventional mouse microbiota (Convmicrobiota).


Inoculating germ-free C57BL/6 wild-type (WT) mice with a mixed human fecal slurry provided a murine model that stably passed its microbiota over >20 generations. Mice were housed in specific pathogen-free (SPF) facilities, while extra precautions of having caretakers wear sterile garb along with limited access ensured that no mouse pathogens were acquired. Humicrobiota conferred many changes upon the WT model in contrast to previous results, which showed only colonization with no disease after C. jejuni challenge. When compared to Convmicrobiota mice for susceptibility to C. jejuni enteric or GBS patient strains, infected Humicrobiota mice had (1) 10-100 fold increases in C. jejuni colonization of both strains, (2) pathologic change in draining lymph nodes but only mild changes in colon or cecal lamina propria, (3) significantly lower Th1/Th17-dependent anti-C. jejuni responses, (4) significantly higher IL-4 responses at 5 but not 7 weeks post infection (PI), (5) significantly higher Th2-dependent anti-C. jejuni responses, and (6) significantly elevated anti-ganglioside autoantibodies after C. jejuni infection. These responses in Humicrobiota mice were correlated with a dominant Bacteroidetes and Firmicutes microbiota.


These data demonstrate that Humicrobiota altered host-pathogen interactions in infected mice, increasing colonization and Th-2 and autoimmune responses in a C. jejuni strain-dependent manner. Thus, microbiota composition is another factor controlling susceptibility to GBS.


Dysbiosis, the depletion of beneficial organisms in the gut microbiota, has been implicated in the manifestation of several autoimmune and chronic inflammatory diseases. Both autoimmune diseases and chronic inflammatory diseases are characterized by destruction of tissues and functional impairment modulated by immune mechanisms [1,2,3]. The microbiota modulates host immune responses and affects the production of cytokines, antibodies, and antimicrobial peptides that target pathogens for removal [4, 5]. Microbial regulation of these immune responses highlights the importance of host-microbiota mutualism. Thus, several autoimmune diseases likely have origins in dysbiotic microbiota or abnormal mucosal barrier function including inflammatory bowel disease (IBD) [6], type 1 diabetes [7], multiple sclerosis [8, 9], and Reiter’s arthritis [10, 11]. A substantial number of autoimmune diseases including Guillain-Barré syndrome [12], Miller-Fisher syndrome [13], and Lyme arthritis [14] have been linked to previous infection with pathogenic organisms [15]. Considerable effort has been made to understand how infection with pathogenic microorganisms results in a loss of tolerance and initiates autoimmunity [15, 16]. One leading hypothesis is that molecular mimicry, a similarity between molecular structures on the infectious agent and host tissues, results in cross-reactivity [17, 18], which in turn leads to autoimmune attack.

Campylobacter jejuni, a leading cause of bacterial gastroenteritis worldwide, precedes at least one-fourth of all cases of the acute peripheral neuropathy Guillain-Barré syndrome [19,20,21]. It is hypothesized that molecular mimicry of host nerve gangliosides such as GM1a, GD1a, and GQ1b by the outer core of lipooligosaccharides on the surface of C. jejuni initiates cross-reactive antibody responses resulting in complement-mediated nerve damage [22]. Other factors may also contribute to Guillain-Barré syndrome (GBS) disease. When enteric disease is severe, C. jejuni infection may be treated with fluoroquinolone or macrolide antibiotics; however, increasing resistance to these drugs has been reported [23]. Notably, antibiotic-treated and gnotobiotic mice display increased susceptibility to C. jejuni colonization and enhanced incidence of gastrointestinal inflammation [24,25,26], leading to the hypothesis that components of the resident mouse gut microbiota protect against Campylobacter-mediated disease [26]. Moreover, approximately two-thirds of GBS patients report gastrointestinal or respiratory inflammation in the weeks preceding neurological symptoms [13, 27,28,29]; thus, host determinants of inflammation including gut microbiota may play a critical role in GBS development. Experimentally, normal flora of mice play a decisive role in preventing C. jejuni-mediated inflammation, thus raising the question of whether murine models carrying certain human microbiota would show similar susceptibility to enteric disease shown in depleted microbiota models [24,25,26].

C57BL/6 IL-10+/+ and IL-10−/− mice function as C. jejuni colonization and colitis models, respectively [30]. C57BL/6 IL-10−/− mice orally infected with isolates from patients with colitis had significantly upregulated type 1 and 17 but not type 2 cytokines in the colon coincident with infiltration of phagocytes, T cells, and innate lymphoid cells (ILCs) [31]. Anti-C. jejuni antibodies generated in this response were of different isotypes; type 1 responses produced IgG2c antibodies, while type 17 responses produced IgG2b antibodies. However, C. jejuni strains from GBS patients induced mild colitis in C57BL/6 IL-10−/− mice associated with blunted type 1/17 but enhanced type 2 responses. Only type 2 antibodies cross-reacted with nerve gangliosides reflecting the roles of Th1/17 responses in killing intracellular pathogens and of Th2 responses in the induction of autoimmunity [31]. These type 2 antibodies were of the IgG1 isotype. We chose the C57BL/6 model to examine the role of the microbiome in eliciting autoimmunity.

To determine if a humanized microbial community is sufficient to alter the host inflammatory and autoimmune response to infection with C. jejuni, we infected C57BL/6 humanized (Humicrobiota) and conventional microbiota (Convmicrobiota) colonized mice with a C. jejuni enteric disease patient strain (11168) or GBS patient strain (260.94). Using an established and robust experimental inoculation system and a defined set of disease indicators [30,31,32], we measured both inflammatory and autoimmune endpoints. We hypothesized that Humicrobiota mice would exhibit (1) enhanced colonization by C. jejuni, (2) higher levels of anti-ganglioside antibodies, and (3) increased lesions in both the GI tract and peripheral nerves compared to mice with Convmicrobiota. To compare the microbiota of Humicrobiota and Convmicrobiota mice, we characterized the fecal microbiota using 16S rRNA gene amplicon analysis. To examine whether the expected microbiota-dependent immune responses resulted in inflammatory changes in the gut (assessed by gross pathology, histopathology, and colon homogenate IFNγ and IL-4 levels) or elevated anti-ganglioside autoantibody levels (determined by plasma antibody ELISA), we infected both Humicrobiota and Convmicrobiota mice with C. jejuni 11168 and C. jejuni 260.94. Here, we show that infected Humicrobiota mice had significantly higher levels of C. jejuni colonization, demonstrable clinical signs of C. jejuni gastroenteritis, and shifts in their adaptive immune responses toward a type 2 biased antibody response with significantly elevated anti-ganglioside autoantibodies when compared to Convmicrobiota mice. These outcomes were affected by the characteristics of the infecting C. jejuni strain as well as by the composition of the gut microbiota. Interestingly, Humicrobiota mice also had diminished activity in the open-field test that was not associated with infection status.



Inoculating germ-free C57BL/6 wild-type (WT) mice with a mixed human fecal slurry provided a murine model that stably passed its microbiota over >20 generations. In two separate experiments (Pilot, Experiment 1), we show that this Humicrobiota conferred many changes upon the WT model that previously showed only colonization with no disease after C. jejuni challenge. Humicrobiota mice infected with either C. jejuni 11168 from a patient with enteritis or C. jejuni 260.94 from a patient with GBS had significant increases in colonization levels compared to infected Convmicrobiota mice. These two groups of infected Humicrobiota mice also had pathologic changes in draining lymph nodes, and colon and cecal lamina propria that were not seen in infected Convmicrobiota mice. The immunologic responses to C. jejuni were also altered in infected Humicrobiota mice with significantly lower Th1/Th17-dependent and higher Th2-dependent anti-C. jejuni responses. The presence of higher Th2-dependent anti-C. jejuni responses were correlated with significantly elevated anti-ganglioside autoantibodies after C. jejuni infection. These responses in Humicrobiota mice were correlated with a dominant Bacteroidetes and Firmicutes microbiota. Both experiments were conducted similarly except that mice were euthanized and necropsied 5 weeks after C. jejuni inoculation in the pilot experiment and 7 weeks after C. jejuni inoculation in Experiment 1.

Pilot experiment

Fecal microbiota

To determine if handling (SPF v sterile) altered the microbiota of Humicrobiota mice, we compared the fecal microbiota of Humicrobiota and Convmicrobiota mice by qPCR. For this analysis, we amplified fecal DNA using 16S rRNA gene primers specific for Clostridium group 14, Clostridium group 1, Bacteroidetes, and Enterobacteriaceae. No statistically significant differences were detected in these four bacterial groups between Humicrobiota mice sham inoculated with tryptose soya broth (TSB) kept under specific pathogen-free (SPF) conditions and Humicrobiota mice sham inoculated with TSB kept under sterile conditions (Additional file 1: Figure S1).

Disease indicators

To determine if Humicrobiota mice were (1) susceptible to C. jejuni gastroenteritis and (2) developed C. jejuni strain-specific antibody responses to GBS patient strains in the Pilot Experiment, we infected mice with either strain 11168 from an enteritis patient or strain 260.94 from a GBS patient or TSB sham inoculated them with the vehicle (Table 1). Veterinarians and trained animal handlers monitored mice for clinical signs daily. A significant difference in body weight was detected between Hu-260.94 and Conv-11168 mice at the time of necropsy (Fig. 1a). A single interleukin-10 (IL-10)-deficient infected mouse with conventional microbiota (Conv-IL-10−/−-11168 (SPF)) displayed severe clinical signs (Fig. 1b). Diarrhea on fur and rough hair coat are the clinical signs most often detected. Gross pathology was mild in all cases, infrequent with the exception of Conv-IL-10−/−-11168 mice, and restricted to infected mice in all cases (Fig. 1c). Interestingly, other than the IL-10-deficient mice, only infected Humicrobiota mice showed gross pathology including thickened cecal and colon wall and enlarged ileocecocolic lymph nodes. C. jejuni 11168 infected C57BL/6 genetically wild-type and IL-10−/− were used as gastroenteritis controls, due to their well-characterized reputation as colitis resistant (wild-type) and colitis susceptible (IL-10−/−) [30, 31]. C. jejuni could be cultured from mice in all infected groups (Fig. 1d–f); however, C. jejuni could be cultured from only 6 of 10 IL-10−/− mice at necropsy. All IL-10−/− mice had C. jejuni-positive fecal samples by culture at semi-quantitative levels of 3 or 4, on day 17 after inoculation showing that all experienced significant colonization. In comparison, 100% colonization at necropsy was achieved in C. jejuni-infected Humicrobiota and Convmicrobiota wild-type (WT) mice, although the WT and IL-10−/− mice were both derived from the same source (The Jackson Laboratory, Bar Harbor, MA).

Fig. 1

Disease indicators: Pilot experiment. (a) body weight at necropsy, (b) clinical signs, (c) gross pathology at necropsy, (d) number of mice that are culture positive for C. jejuni in cecum or colon, and semi-quantitative representation of culturable C. jejuni in (e) colon and (f) cecum at necropsy. Panels g-m represent anti-Campylobacter (g-j) and anti-ganglioside antibodies (k-m) detected by indirect ELISA. Bars indicate statistical significance. Data were analyzed by Kruskal-Wallis test on ranks and Dunn’s post-test where appropriate; p≤0.05 considered statistically significant. The microbiota type of the mouse is indicated as Hu (Human microbiota) or Conv (Conventional microbiota) followed by their treatment group

Mice with Humicrobiota had greater TH2-dependent IgG1 responses to the enteric strain of C. jejuni, but lower such responses to the GBS strain

To assess specific immune reactivity and cross-reactive antibody responses, we measured anti-C. jejuni and anti-ganglioside antibody responses in infected mice by indirect enzyme-linked immunosorbent assay (ELISA). Presence of a human microbiota altered the response to the C. jejuni 11168 enteritis strain. Anti-C. jejuni IgG2c (TH1 associated) and IgG2b (TH17 associated) antibodies to 11168 were elevated compared to the TSB sham inoculated controls in Humicrobiota C57BL/6 mice (Fig. 1g, i). However, the degree of elevation of both of these antibody isotypes was significantly lower in Humicrobiota mice than in Convmicrobiota mice given the same C. jejuni strain (Fig. 1g, i). Furthermore, Humicrobiota mice given C. jejuni 11168 mounted a significantly higher anti-Campylobacter T helper 2 (TH2)-biased IgG1 response, which was virtually absent in Convmicrobiota mice (Fig. 1j). Thus, having this human microbiota was sufficient to skew T helper cell responses to the enteric strain of C. jejuni toward an antibody-mediated adaptive response. Some Humicrobiota mice infected with the C. jejuni 260.94 GBS strain had mild elevations in mixed TH1,/TH17/TH2 antibody responses, but these were not significant when compared to uninfected controls (Fig. 1gj).

Mice with Humicrobiota had greater anti-ganglioside autoantibody responses than mice with Convmicrobiota

Presence of this human microbiota was sufficient to stimulate anti-ganglioside autoantibodies against the C. jejuni 11168 enteric strain that has not been previously associated with development of GBS. There were significantly increased anti-GD1a and anti-GM1a/GQ1b IgG1 autoantibodies in Humicrobiota mice infected with the C. jejuni 11168 enteric strain compared to Convmicrobiota mice given the same strain (Fig. 1l, m). Also, despite the low anti-C. jejuni IgG1 antibody responses to the C. jejuni 260.94 strain, the IgG1-dependent anti-ganglioside antibody responses (GM1, GD1a, GM1/GQ1b) to the GBS strain 260.94 were significantly elevated in Humicrobiota mice compared to Convmicrobiota mice given strain 11168 (Fig. 1k–m). Thus, infection with either of C. jejuni strains 260.94 or 11168 elicited anti-ganglioside autoantibodies, but only in Humicrobiota mice. TH2-associated (IgG1) anti-ganglioside responses were elevated in some cases independent of inoculation status, suggesting a TH2-associated antibody bias in Humicrobiota mice (Fig. 1l, m). This is reflected in the responses seen in TSB sham-inoculated uninfected control mice managed by either sterile or SPF techniques (Fig. 1l, m). This suggests that other pathogen-associated molecular patterns (PAMPs) from the microbiota may also cause ganglioside mimicry.

Experiment 1

Humicrobiota mice have a distinct microbiota compared to Convmicrobiota mice

In Experiment 1 (Table 2), to compare microbiota structure in Humicrobiota and Convmicrobiota, infected and TSB sham inoculated mice, we analyzed their fecal microbiota with 16S rRNA gene amplicon analysis. Analysis revealed that 4 of 5 phyla, 9 of 11 classes and 32 of 52 genera detected in the human fecal slurry used to produce the Humicrobiota mice could be detected in the Humicrobiota mice utilized in this study. The phylum Verrucomicrobia constituted less than 2% of the reads from the original inoculum and could not be found in Humicrobiota mice used in this experiment. Noteworthy was that clustering of groups based on Bray-Curtis dissimilarity statistic resulted in separation by microbiota but not group assignments according to C. jejuni or TSB sham inoculation (Fig. 2).

Table 1 Experimental design: pilot experiment. C57BL/6 wild-type (C57BL/6) or congenic C57BL/6 IL-10-deficient (C57BL/6 IL-10−/−) mice with humanized (Hu) or conventional (Conv) microbiota were inoculated with TSB, C. jejuni 260.94, or C. jejuni 11168 and subjected to sterile (Ster.) or specific pathogen-free (SPF) handling for the duration of the experiment; 5 weeks post-inoculation
Table 2 Experimental Design: Experiment 1. C57BL/6 genetically wild-type mice with humanized (Hu) or conventional (Conv) microbiota were inoculated with TSB, C. jejuni 260.94, or C. jejuni 11168 and subjected to specific pathogen-free (SPF) handling for the duration of the experiment; 7 weeks post-inoculation
Fig. 2

Heat map of relative OTU abundance across samples. Abundances were measured as proportions of samples and the 60 most abundant OTUs are shown. Samples and OTUs were clustered hierarchically based on relative abundance profiles. On the right y-axis labels represent individual samples starting with group labels. Group labels; HI2= Humanized-Infected-260.94, HUT= Humanized-Uninfected-TSB, HI1= Humanized-Infected-11168, CI2= Conventional-Infected-260.94, CUT= Conventional-Uninfected-TSB, CI1= Conventional-Infected-11168, INO= Inoculum. The left y-axis represents the color-coded groups shown in the legend. OTUs are represented on the x-axis with corresponding relative abundances shown in the heatmap grid with increasing abundance from light green to black

There was an increased abundance of Lactobacillus in Convmicrobiota mice

Five bacterial orders had an average abundance of 5% or greater in one or more groups of mice; Bacteriodales, Bifidobacteriodales, Clostridiales, Lactobacillales, and Erysipelotrichales (Fig. 3ae). Bacteriodales was a minor component of the inoculum, constituting approximately 3.3% of the sequences, but a major component of Humicrobiota (~57–60%) and Convmicrobiota (28–43%) (Fig. 3a). Within the order Bacteriodales, the Humicrobiota was dominated by Bacteroidaceae (~58–63% of Bacteriodales) yet it was only a minor component of the conventional murine microbiota (~0.02–0.07% of Bacteriodales). In contrast, within the order Bacteriodales, the murine Convmicrobiota was dominated by Porphyromonadaceae (~98% of Bacteriodales). Bifidobacteriodales constituted ~7% of the inoculum, was completely absent in the Humicrobiota mouse samples, and was a minor component of the Convmicrobiota (~0.6–1.6%) (Fig. 3b). All reads from the order Bifidobacteriodales were assigned to the family Bifidobacteriaceae. The inoculum was dominated by the order Clostridiales (~70%), which was less abundant in all of the mouse fecal samples but present in similar abundances in Humicrobiota (~28–38%) and Convmicrobiota (22–42%) samples (Fig. 3c). Within the order Clostridiales, Lachnospiraceae was the dominating family in all groups. Erysipelotrichales was also present in all mice and was more abundant in Convmicrobiota mice than in the inoculum or Humicrobiota mouse samples; inoculum (7.2%), Humicrobiota (~3.6–4.5%), and Convmicrobiota (~10.4–15.1%) (Fig. 3d). Lactobacillales was present in all groups but more abundant in the Convmicrobiota mice than in the inoculum or in Humicrobiota mice; inoculum (0.68%), Humicrobiota (~0.002–1.7), and Convmicrobiota (~2.9–6.3%) (Fig. 3e). Within the order Lactobacillales, Humicrobiota mice had no or 6000-fold less Lactobacillaceae than Convmicrobiota mouse samples. In all cases, greater than 97% of the reads in the family Lactobacillaceae were assigned to the genus Lactobacillus (Fig. 3f). At the order level, unclassified reads could be found in all groups; inoculum (3.7%), Humicrobiota (~1.9–2.4%), and Convmicrobiota (~9.2–10.4%) (data not shown).

Fig. 3

Relative abundance of major bacterial orders in fecal microbiota (a-f). Data represent relative abundances of OTUs assigned at the Order level with the exception of the family Lactobacillaceae. Orders constituting ≥5% of the average abundance for a single group were included. The average percentage of reads within each order that were assigned to families are represented as proportions of the orders bar

Diversity statistics showed that groups can be distinguished by microbiota but not infection status

To determine if operational taxonomic units (OTUs) could be separated into groups based on microbiota or inoculation status, we assessed OTUs by alpha and beta diversity metrics. Principal components analysis showed that there was clear separation between Humicrobiota and Convmicrobiota fecal samples (Fig. 4a) but that microbiota composition was not affected by inoculation status (Fig. 4b, c). These results are supported by two-way ANOSIM and PERMANOVA (Fig. 4d). Comparison of alpha diversity metrics revealed a disparity in OTUs in Hu-11168 compared to Conv-11168 (P = 0.0310) (Fig. 5a). No other disparity in alpha diversity of OTUs existed, and this finding was not reflected in species diversity or evenness (Fig. 5bd).

Fig. 4

Principal component analysis (PCA) and multivariate statistics of 16S rRNA taxonomy. PCA modeling was performed using OTU assignments. Resulting plots show separation by microbiota (a) but not inoculum (b and c). Dots represent; dark blue = Conv-11168, blue = Conv-260.94, light blue = Conv-TSB, dark green = Hu-11168, green = Hu-260.94, light green = Hu-TSB, and red = Inoculum. d Two-way ANOSIM and two-way PERMANOVA indicate statistically significant differences between microbiota but not the inoculum

Fig. 5

Alpha-diversity indices for 16S rRNA gene sequences. Panels represent (a) observed OTU’s, (b) estimated richness (Chao1), (c) species evenness (Pielos), and (d) species diversity (inverse Simpson). Data were analyzed by Kruskal-Wallis test on ranks and Dunn’s post-test; P≤0.05 was considered statistically significant. Whiskers represent minimum and maximum values. All other points are contained within the box and the bar represents the median

The majority of the variance between TSB sham-inoculated Humicrobiota and Convmicrobiota mice can be attributed to the abundance of Porphyromonadaceae, Bacteroidaceae, and Lachnospiraceae

To determine (1) which OTUs varied in abundance between groups and (2) the contribution of distinct OTUs to the variance between groups, we performed a paired T test with a Benjamin-Hochberg correction for false discovery ( and similarity percentages analysis. In summary, Humicrobiota and Convmicrobiota samples could be distinguished by OTUs assigned to the Bacteroidetes and Firmicutes phyla, and these phyla contributed to 57.19 and 26.6% of the variance between TSB sham-inoculated Humicrobiota and Convmicrobiota mice, respectively (Table 3). The most abundant OTUs contributing to the difference between the groups are OTUs 002, the dominant OTU in the Convmicrobiota samples, and OTUs 001 and 003, which are the dominant OTUs in the Humicrobiota samples. Collectively, OTUs 001, 002, and 003 contribute 57.93% of the variance between TSB sham-inoculated Humicrobiota and Convmicrobiota mice.

Table 3 Contribution of taxa to group differences. The average read abundance of OTUs that distinguish the Hu-TSB and Conv-TSB based P values were determined by paired T test with Benjamin-Hochberg correction for multiple comparisons. Contribution to variance was determined by Similarity Percentages (SIMPER) analysis

Eigenvalues and loadings for the principal components analysis shown in Fig. 4 are given in Additional file 2 Table S1 and are similar to the results of the similarity percentages analysis. Both inspection of the scree plot (not shown) and application of the Joliffe cutoff to the eigenvalues indicate that the first four axes are the most significant axes. In the PCA, the eigenvalues of the first two axes together account for 89.6% of the variance; loadings indicate that the first axis of the PCA, which separates humanized from conventional microbiota mice, is dominated by OTUs 2 and 3 (unclassified member of the family Prophyromonadaceae and a member of the genus Bacteroides, respectively). Axis 2 is dominated by OTUs 1 and 3 (unclassified member of the family Lachnospiraceae and a member of the genus Bacteroides, respectively).

Additional file 3: Table S2 lists a relatively small number of OTUs identified by mothur as significantly associated with either humanized or conventional microbiota mice (i.e., indicator OTUs). Because the genus Lactobacillus appears in the conventional microbiota list, it is tempting to speculate that the organism represented by this OTU is protective against Campylobacter colonization or modulates immune responses in conventional microbiota mice or both. However, it is important to note that not all species, or even all strains within a species, of the genus Lactobacillus have probiotic effects. It is equally possible that some process carried out by one or more of the organisms represented by the OTUs in the humanized microbiota mice list enables Campylobacter colonization or modulates immune responses toward Th2 pathways in humanized microbiota mice.

Disease indicators: Humicrobiota mice displayed increased susceptibility to intestinal inflammation

To compare the progression and severity of disease in experimental mice, we monitored all mice for (1) clinical signs, (2) gross pathology, and (3) disparity in body weight. All mice were monitored closely by veterinarians to determine if euthanasia was required prior to the scheduled 7-week endpoint. These determinations were based on hunching, lethargy, and watery or bloody diarrhea in accordance with a standardized scoring system [30] available from the Michigan State University Microbiology Research Unit Food and Waterborne Diseases Integrated Research Network-sponsored Animal Model Phenome Database for gastrointestinal disease and another score sheet developed to monitor development of neurological disease that might have developed in mice given the GBS-associated C. jejuni strain 260.94 [33]. No severe disease indicators were detected during the experimental course that exceeded the scoring limit of 9 for humane euthanasia, thus all of the mice were maintained for the entirety of the experiment. No significant differences in body weight were detected, although some Humicrobiota mice were heavier than Convmicrobiota mice in all groups (Fig. 6a). Clinical signs were detected mainly in two groups, those that were Humicrobiota mice infected with either C. jejuni 260.94 or 11168 (Fig. 6b). Six of ten Humicrobiota mice infected with C. jejuni 260.94 had episodes of soft feces, hunched posture, rough hair coat, and reduced activity over the 7-week period; six of ten Humicrobiota mice infected with C. jejuni 11168 also had episodes of soft feces, hunched posture, rough hair coat, and reduced activity over the 7-week period. During this period, only one of ten Convmicrobiota mice given C. jejuni 260.94 or 11168 had soft feces and no other clinical signs. Control mice had virtually no clinical signs except for one sham-inoculated Convmicrobiota mouse judged to have reduced activity on one occasion and two sham-inoculated Humicrobiota mice judged to have a rough hair coat on one occasion. Four of ten C. jejuni 260.94 infected and five of ten C. jejuni 11168 infected Humicrobiota mice had severe gross pathological changes in the GI tract (Fig. 6c). In many of these cases, the ileocecocolic lymph node, spleen, and sometimes the mesenteric lymph nodes were enlarged. One C. jejuni 11168 infected Humicrobiota mouse had a slightly thickened colon wall. To determine if the level of C. jejuni differed between Humicrobiota and Convmicrobiota mice, a potential cause of enhanced GI gross pathology, we quantified C. jejuni in both the cecum and colon. Colonization was significantly higher in Humicrobiota than Convmicrobiota mice (Fig. 6e, f). These data were supported by a 10- and 100-fold increase in Campylobacter reads in Humicrobiota fecal microbiota analysis of mice infected with C. jejuni strains 11168 and 260.94, respectively, compared to Convmicrobiota fecal microbiota samples (Fig. 6g). We processed the ileocecocolic junctions for histopathologic evaluation of the ileum, cecum, and colon and found that although a few C57BL/6 Humicrobiota mice had higher scores than their congenic Convmicrobiota counterparts, gastrointestinal lesions were mild and not significantly different between groups. Thus, the main changes associated with experimental C. jejuni infections were in secondary lymphoid tissues including the ileocecocolic lymph nodes, the mesenteric lymph nodes, and the spleen in Humicrobiota mice.

Fig. 6

Humicrobiota mice are more susceptible to C. jejuni colonization, GI inflammation and antiganglioside antibodies than Convmicrobiota mice. Data represent (a) body weight at necropsy, (b) clinical signs, (c) gross pathology, (d) ileocecocolic histopathology scores, (e) culturable C. jejuni in colon, (f) culturable C. jejuni in cecum, and (g) percentage of 16S rRNA amplicons assigned to the genus Campylobacter. Panels h to k are isotype specific anti-Campylobacter antibody responses in plasma detected by indirect ELISA. Panels l, m and n show anti-ganglioside antibody responses in plasma detected by indirect ELISA. Data were analyzed by Kruskal-Wallis test on ranks and Dunn’s post-test where appropriate; p≤0.05 considered statistically significant

Mice with Humicrobiota had greater TH2-dependent IgG1 responses to both enteric and GBS strains of C. jejuni

To assess specific immune reactivity and cross-reactive antibody responses, we measured anti-C. jejuni and anti-ganglioside antibody responses in infected mice by indirect ELISA. Both Humicrobiota and Convmicrobiota mice mounted anti-C. jejuni IgG2c (TH1 associated) and IgG2b (TH17 associated) antibody responses to 11168 when compared to their respective TSB sham-inoculated controls (Fig. 6h, j). However, the anti-C. jejuni IgG2b responses to strain 11168 in Humicrobiota mice were significantly higher than in Convmicrobiota mice, while the anti-C. jejuni IgG2c responses were not significantly different between these groups (Fig. 6h, j). This may simply indicate that anti-C. jejuni T helper 1 (TH1) responses wane faster than TH17 responses in this model at the 7-week time point. Yet the anti-C. jejuni IgG2c (TH1 associated) and IgG2b (TH17 associated) antibody responses to 260.94 were higher in this experiment, with Humicrobiota mice producing significantly higher anti-C. jejuni IgG2c responses than Convmicrobiota mice (Fig. 6h, j). Furthermore, Humicrobiota mice produced significantly higher anti-C. jejuni IgG1 responses than Convmicrobiota mice to both C. jejuni strains (Fig. 6k). In TSB sham-inoculated mice, TH2-associated anti-Campylobacter IgG1 antibody responses were elevated in Humicrobiota mice compared to Convmicrobiota mice, indicating a TH2-associated antibody bias in Humicrobiota mice that was not associated with the presence of the inoculating bacterium (Fig. 6k). This was consistent with results in the pilot experiment. Finally, the anti-C. jejuni IgG3 responses to strain 11168 in Humicrobiota mice were significantly higher than those seen in Convmicrobiota mice given TSB or C. jejuni 260.94 (Fig. 6i). Significant elevations in anti-C. jejuni IgG3 responses were seen in Convmicrobiota mice given C. jejuni 11168 compared to those given TSB or C. jejuni 260.94 but these responses were minimal (Fig. 6i).

Mice with Humicrobiota had greater anti-GM1 ganglioside antibody responses than mice with Convmicrobiota

Based on the pilot experiment and because IgG1-specific anti-ganglioside responses have been associated with development of GBS in human patients, we measured anti-GM1 and GD1a single ganglioside responses in Experiment 1. Similarly to the pilot experiment results, we found that Humicrobiota mice infected with C. jejuni 260.94 had significantly elevated anti-GM1 IgG1 antibodies when compared to Convmicrobiota mice infected with the same strain (Fig. 6l). However, unlike results in the pilot experiment, Humicrobiota mice infected with C. jejuni 11168 had significantly elevated anti-GM1 IgG1 antibodies when compared to the sham-inoculated Convmicrobiota mice, but not when compared to the Convmicrobiota mice infected with the same strain (Fig. 6l). This difference correlated with slightly lower anti-Campylobacter and anti-ganglioside antibodies at 7 weeks post infection versus 5 weeks post infection in the pilot experiment (Figs. 1gm and 6hn). No significant anti-GD1a or anti-GM1/GQ1b responses were seen.

C. jejuni 11168-infected Humicrobiota mice had significantly higher IL-4 colon responses at 5 but not 7 weeks post infection

After conducting both the pilot experiment and Experiment 1, we processed snap frozen colon tissues for measurement of TH1-associated inflammatory (IFNγ) and TH2-associated anti-inflammatory (IL-4) mRNA levels using RT-PCR. At 5 weeks post infection (PI) in the pilot experiment, C. jejuni 11168-infected Humicrobiota mice had significantly higher IL-4 colon responses when compared to TSB sham-inoculated controls and to Convmicrobiota mice infected with the same strain (Fig. 7b). No other significant differences in cytokine measurements were seen at either 5 or 7 weeks post infection in either experiment (Fig. 7ad). In Experiment 1, three high reactor mice were detected for IL-4 responses in the following groups, Hu-260.94 (19.4-fold increase/HPRT compared to group mean of 1.7), Hu-260.94 (17.8-fold increase/HPRT compared to group mean of 1.7), and Hu 11168 (38.3-fold increase/HPRT compared to group mean of 5.244) (Fig. 7d). There was a single high reactor for IFNγ responses in Humicrobiota mice given C. jejuni 11168 (Fig. 7c). These high reactors correlated with C. jejuni infection status and the otherwise low responses at 7 weeks PI likely reflect waning of early colon responses. Subsequent analyses were conducted to determine if C. jejuni infection initiated autoimmune responses to peripheral nerves consistent with the predicted mechanism of GBS. To determine if macrophage numbers in sciatic nerves and dorsal root ganglia were increased in C. jejuni-infected mice compared to controls, we immunohistochemically labeled these tissues with anti-F4/80 antibody and counted positive cells. No differences in peripheral nerve lesions were detected.

Fig. 7

C. jejuni infected Humicrobiota mice have significantly elevated colon IL-4 cytokine responses at five but not seven weeks post infection when compared to sham inoculated Humicrobiota mice or C. jejuni infected Convmicrobiota mice. Panels represent fold change in interferon gamma (IFN-γ) (a and c) and IL-4 responses (b and d) over responses of the sham inoculated mice. Panels a and b are from mice in the Pilot experiment sacrificed at 5 weeks post infection while panels c and d are from mice in Experiment 1 sacrificed at 7 weeks post infection. IFN-γ and IL-4 mRNA levels were measured in proximal colon homogenates from all mice in the respective groups shown on the X axis. Data were analyzed by Kruskal-Wallis test on ranks and Dunn’s post-test where appropriate; p≤0.05 was considered statistically significant

Humicrobiota mice display hypoactivity in the open-field test and infection alters activity in mice with Convmicrobiota

To determine if C. jejuni infection was associated with behavioral phenotypes indicative of enteric disease or peripheral neuropathy, we recorded the activity of the experimental mice in the open-field test. In general, mice with Humicrobiota displayed diminished activity levels compared to Convmicrobiota mice regardless of infection status (Fig. 8a, b), and both groups trended toward a decrease in activity as time progressed. Significant decreases in the number of quadrants crossed were primarily dependent upon having Humicrobiota; no differences were detected within the Humicrobiota mice during the 7 weeks, and they generally displayed low levels of activity. After week 3, no differences in rearing behavior were detected between any groups as mice were generally inactive.

Fig. 8

Behavioral phenotyping in the open-field test. Number of (a) Quadrants crossed and (b) Rears in the open-field one-week prior to inoculation (i.e. baseline) and 1 to 7 weeks post-inoculation. Boxes represent 95% confidence intervals and whiskers represent range. Lines represent the median of Convmicrobiota (red) and Humicrobiota (blue) mice regardless of inoculation status. Data were analyzed by repeated measures two-way analysis of variance (ANOVA) and Tukey’s post-test; p≤0.05 indicates statistical significance (reported in results). The key shows the color of each experimental group


C. jejuni is a leading cause of bacterial diarrheal illness and the leading antecedent infection to the autoimmune acute peripheral neuropathy GBS [21, 34]. In previous work, we developed mouse models of both enteric and subsequent neurologic disease associated with C. jejuni infection [30, 31, 33, 35]. In the experiments reported here, we explored the influence of the gut microbiota on these disease manifestations. After six generations of breeding, individually housed C57BL/6 mice with a transplanted human microbiota were infected with C. jejuni enteric disease or GBS patient strains. These mice retained a microbiota distinct from that of their Convmicrobiota counterparts that could be primarily distinguished by bacteria belonging to the phyla Bacteroidetes and Firmicutes. C. jejuni infection did not appear to alter the microbiome composition in either group (Fig. 4b, c). Moreover, the abundance of Lactobacillus, which has been shown to prevent C. jejuni colonization in in vivo and in vitro models [26, 36], was at least 6000-fold greater in Convmicrobiota than Humicrobiota mice. Consistent with those results [26, 36], semi-quantitative and 16S rRNA gene amplicon analysis showed that microbiota source affected C. jejuni load. Ten-fold higher C. jejuni 11168 and 100-fold higher C. jejuni 260.94 loads were detected in the fecal microbiota of infected Humicrobiota mice than their Convmicrobiota-matched counterparts (Fig. 6g). Furthermore, the presence of this Humicrobiota skewed adaptive T cell responses to C. jejuni. Mice with Humicrobiota had greater TH2-dependent IgG1 responses to both enteric and GBS strains of C. jejuni and greater anti-GM1 ganglioside antibody responses than mice with Convmicrobiota. These results confirm that this T cell skewing favored development of autoimmune antibodies directed against nerve gangliosides, which is a hallmark of a GBS response. Additionally, we observed that this Humicrobiota caused mixed TH1/TH17/TH2-associated responses to occur to a strain of C. jejuni 260.94 that was previously shown to produce only TH2 responses in C57BL/6 IL-10−/− mice with Convmicrobiota [31]. The shift in T cell responsiveness in the experiments reported here was accompanied by the occurrence of distinct disease manifestations in the GI tract and the presence of anti-ganglioside antibodies in infected Humicrobiota mice as compared to the infected or uninfected Convmicrobiota mice. C. jejuni 11168 or 260.94 infected Humicrobiota mice had increased gross gastrointestinal lesions, which was not seen previously in Convmicrobiota mice of the same genotype from the same breeding colony [31]. Overall, our results support the conclusion that components of the murine microbiota play a role in colonization resistance that is overcome in our Humicrobiota model, resulting in increased susceptibility to both inflammation and autoimmunity.

We analyzed C. jejuni-infected mice with Humicrobiota and Convmicrobiota for enteric inflammation and found that Humicrobiota mice are more susceptible to C. jejuni-mediated inflammation determined by having more severe gross pathology especially enlarged lymph nodes. These results are consistent with previous reports showing that the microbiota is a key regulator of enteric disease in C. jejuni-infected mice [24,25,26]. Despite this finding, significant enteric histologic lesions were not found and inflammatory cytokine levels were not significantly elevated in the proximal colon of Humicrobiota mice. These results suggest that most of the immune reactivity was occurring in the draining lymph nodes and not in the colon wall in most infected mice. We previously reported that interleukin-10 deficiency significantly increased host-inflammatory responses to C. jejuni. Now these results indicate that ecological shifts in the microbiota are another factor sufficient to enhance host susceptibility to C. jejuni resulting in mild enteric disease in IL-10-sufficient mice.

Infection with C. jejuni GBS patient strains is associated with TH2 immune responses and anti-ganglioside antibodies in a C57BL/6 IL-10-deficient mouse model [31]. In these experiments, Humicrobiota mice showed a type 2-biased antibody response with or without infection compared to Convmicrobiota mice. Analysis of anti-ganglioside antibodies showed exacerbated anti-GM1 antibody levels following infection with C. jejuni 260.94 but not enteric strain 11168 compared to Convmicrobiota mice infected with the same C. jejuni strain. We have demonstrated microbiota-mediated autoimmunity in C. jejuni-infected mice with depleted microbiota previously (Brooks et al. unpublished); however, this is the first study to show that ecological shifts in a diverse microbial community are sufficient to alter C. jejuni-mediated autoimmunity. In fact, while TH1/TH17 responses (IgG2c, IgG2b) to the C. jejuni 11168 strain in Humicrobiota mice are similar to those in IL-10-deficient mice, Humicrobiota mice have more pronounced TH2 responses to C. jejuni 11168 than IL-10-deficient mice and yet displayed no demonstrable nerve lesions of GBS. This result suggests that anti-ganglioside antibodies alone cannot produce GBS in the Humicrobiota C57BL/6 mice where IL-10 is present. These results, in conjunction with anti-Campylobacter-specific antibody results show that differences in the lipooligosaccharide outer core antigens presented on the two C. jejuni strains are not the only factor driving enteric and GBS phenotypes. In addition, presence of C. jejuni 11168 IgG1 antibody responses also suggest that the 11168 strain is not strictly an enteritis-causing strain. Although it was taken from a human patient with acute gastroenteritis, the possibility that a single strain could cause different manifestations of disease in different individuals, perhaps even depending on the microbiota composition of those individuals, should not be discounted.

A significant decrease in activity in the open-field test was detected in all Humicrobiota mice, while overt neurological signs of GBS were not significantly elevated in the infected versus TSB sham-inoculated groups. The open-field test has been used as a non-invasive longitudinal measure of quality of life that allows the investigator to make inferences about anxiety and normal exploratory behavior [37,38,39]. It also can be used to assess ambulation and rearing that when quantified with the JWatcher software can provide indication of motor and proprioception impairment. Our mice were observed by veterinarians trained to assess neurological behavior in animals. However, this decrease in activity was not due to infection status, nor were there any severe clinical signs of neurologic or enteric disease detected in the Humicrobiota mice; thus we conclude that this decreased activity is not an indicator of nervous system disease in response to infection. Moreover, sciatic nerves and lumbar dorsal root ganglia were dissected and immunohistochemically labeled and macrophages quantified to determine whether an increase in macrophages could be detected as a potential mechanism of peripheral nerve damage consistent with that seen in patients with GBS [12, 21, 40]. An increase in macrophages in or around the nerve is indicative of complement-dependent injury; however, no differences in macrophage numbers were detected in our study. Furthermore, mere changes in weight of the mice were not great enough to explain this inactivity. Thus, our results suggest the possibility of an influence of the microbiota on brain and behavior, which has been shown previously [41,42,43]. Taken together, these findings suggested that the particular microbiota influenced stress responses in the Humicrobiota mice independent of the infection status. Further investigation is required to determine the origin of this response in the Humicrobiota mice.

In summary, we found that the microbiota is a key factor in the regulation of Campylobacter inflammation in the intestine and the elicitation of anti-ganglioside antibodies. These data support recent findings that the microbiota is a critical component in Campylobacter gastroenteritis and, to our knowledge, this is the first report to suggest that the microbiota may in fact be a determinant of host susceptibility to Guillain-Barré syndrome. C. jejuni microbiota-mediated colonization resistance in mice is overcome by perturbation of the microbiota; thus factors that alter the host microbiota such as age, diet, antibiotic treatment, and prior pathogen exposure may be determinants of susceptibility to Guillain-Barré syndrome. Because no single human microbiota exists, it is reasonable to speculate that OTUs distinguishing the human and murine microbiota in our experimental mice play a role in regulating C. jejuni loads. Finally, therapeutic approaches that avoid depletion of healthy microbiota and enhance populations of beneficial microorganisms may be appropriate. Recently, probiotics, including Lactobacillus, have been shown to inhibit C. jejuni growth in mice [26]; thus probiotic supplementation during the early stages of infection may facilitate clearance of C. jejuni [44].


These data demonstrate that Humicrobiota altered host-pathogen interactions in infected mice, increasing colonization and Th-2 and autoimmune responses in a C. jejuni strain-dependent manner. This demonstrates that colonic microbiota composition is another factor controlling susceptibility to GBS. This study and the resulting animal model provides the basis for understanding how these autoimmune neurological responses arise secondary to an important foodborne pathogen.


Laboratory animals

C57BL/6J and C56BL/6 IL-10−/− mice were obtained from The Jackson Laboratories (Bar Harbor, ME). A breeding colony was established in a Campylobacter/Helicobacter-free facility, and the MouSeek database (Caleb Davis, Baylor College of Medicine, Houston, TX) was used to track all mice bred and used throughout the study. Germ-free C57BL/6J mice were also obtained from the same containment building at The Jackson Laboratories. All mouse experiments were performed according to recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. Protocols were reviewed and approved by the Michigan State University Institutional Animal Use and Care Committee (approval numbers 06/12-107-00 and 06/15-101-00). Age-matched male and female mice were used for all experiments. A portion of the mice in each experiment possessed humanized microbiota generated as described previously [45] and are indicated with the prefix Hu (Humicrobiota). Briefly, germ-free mice were inoculated by gavage with a human fecal slurry, bred, and the microbiota allowed to pass from mother to offspring without intervention within the germ-free incubator. After initial characterization in founder mice described in Collins et al. 2015 [45], the Humicrobiota mice were separated into two groups, and a new colony was established (Hu-C57BL/6) by LS Mansfield by transferring mice in sterile filter top cages within sterile dog crates to Michigan State University. Humicrobiota mice were housed under specific pathogen-free conditions (SPF), and bred for six generations in closed cages on an Innovive (San Diego, CA, USA) mouse rack with filtered air flow and sterile food and water. All cage changes and other manipulations were performed in a laminar flow hood with gowned and gloved personnel using sterile technique to avoid introduction of microorganisms from the environment.

In the pilot experiment, age-matched 10–12-week-old Humicrobiota C57BL/6 genetically wild-type (Hu), conventional microbiota genetically wild-type (Convmicrobiota), and Convmicrobiota congenic IL-10-deficient mice (Conv-IL-10−/−) were used. Mice were inoculated with either tryptone soy broth (TSB; vehicle control), C. jejuni 260.94, or C. jejuni 11168 and handled with sterile or specific pathogen-free (SPF) technique resulting in six groups (Table 1). For SPF technique, all personnel that were handling animals wore Tyvek coveralls, impermeable plastic booties, face mask, hair bonnet, and gloves. All cage changes were performed on a laminar flow cage changing station. For sterile technique, all personnel that were handling animals wore impermeable plastic booties, face mask, hair bonnet, sterile surgical gown, and sterile surgical gloves. All breeding mice were and continue to be handled using sterile technique to avoid introducing extraneous organisms to the microbiota. All cage changes for breeding mice were performed in a sterile laminar flow hood that was disinfected after each use. To determine if handing would alter outcomes in TSB sham-inoculated Humicrobiota mice, we inoculated 20 Humicrobiota mice with TSB and handled them with either sterile technique (Hu-TSB (Ster.)) or SPF technique (Hu-TSB (SPF)). Two other Humicrobiota groups were generated by inoculating Humicrobiota mice with either C. jejuni 260.94 (Hu-260.94 (Ster.)) or C. jejuni 11168 (Hu-11168 (Ster.)) and handling them with sterile technique. As a positive control for gastroenteritis, we inoculated and compared outcomes in Convmicrobiota wild-type C57BL/6 and C57BL/6 IL-10−/− mice inoculated with C. jejuni 11168 and handled with SPF technique. Mice were sacrificed at 5 weeks post-inoculation.

In Experiment 1, age-matched C57BL/6 Humicrobiota and Convmicrobiota mice were inoculated with TSB, C. jejuni 260.94, or C. jejuni 11168 (Table 2). In Experiment 1, all mice were handled with SPF technique, observed for 7 weeks post-inoculation, and then sacrificed. In all, six experimental groups were generated in Experiment 1; Convmicrobiota TSB inoculated (Conv-TSB), Convmicrobiota C. jejuni 260.94 infected (Conv-260.94), Convmicrobiota C. jejuni 11168 infected (Conv-11168), Humicrobiota TSB inoculated (Hu-TSB), Humicrobiota 260.94 infected (Hu-260.94), and Humicrobiota 11168 infected (Hu-11168).

Enteric pathogen screening

DNA was extracted from feces collected from all mice before experimental inoculation and at necropsy for enteric pathogen screening as described [30]. In all cases, no control mice were positive for C. jejuni PCR using gyrA-specific primers [46]. Also, we screened all samples for Campylobacter spp. (16S rRNA gene), Helicobacter spp. (16S rRNA gene), Citrobacter rodentium (espB gene), and Enterococcus faecalis (ddl gene). Dedicated sentinel mice were used to assess extraneous infection with bacteria, protozoa, and viral agents (Charles River Laboratories, Wilmington, MA) and were monitored by the MSU Campus Animal Resources (CAR).

C. jejuni strains and inoculum preparation

C. jejuni strains 260.94 (ATCC BAA-1234) and NCTC 11168 (ATCC 700819) were obtained from the American Type Culture Collection (Manassas, VA). C. jejuni 260.94 is a Guillain-Barré syndrome patient strain that elicits GM1 and GD1a anti-ganglioside antibody responses in C57BL/6 IL-10−/− mice [31]. C. jejuni 11168 is an enteric disease patient strain isolated from a patient with severe gastroenteritis. C. jejuni 11168 has a GM1 ganglioside mimic on its surface [47] but is not associated with GBS and has not been shown to elicit significant anti-ganglioside antibody responses in C57BL/6 IL-10−/− mice [31]. Inocula were prepared in the same manner for both experiments. Inocula of both C. jejuni strains were prepared by streaking frozen stocks onto tryptone soy agar (TSA) (Accumedia) supplemented with 5% defibrinated sheep blood (Cleveland Scientific, Bath Ohio) (TSAB). Plates were incubated at 37 °C in anaerobic jars equilibrated to 10% CO2, 10% H2, and 80% N2 for 48 h and a portion of the growth re-suspended in tryptone soya broth (TSB) to give an A600 of 0.2 to 0.3. One-hundred microliters of this suspension was spread on two plates per mouse and the plates incubated for 16 h in the 10% CO2, 10% H2, and 80% N2 gas mixture. The resulting cells were collected and suspended in TSB; the suspension was adjusted to give an A600 of approximately 1.0 when diluted 1:10 (approximately 1 × 1010 CFU/mL final concentration). Purity, morphology, and motility were verified by microscopy and Gram straining. Finally, 0.2 mL per mouse of the resulting inoculum or the vehicle (i.e., TSB) was carried to the containment facility on ice and delivered to infected and control mice, respectively, by oral gavage, resulting in six groups (Tables 1 and 2). Limiting dilution analysis was used to determine the actual titer of the inoculum delivered to the mice.

Experimental design

Following infection, all mice were observed at least once daily (twice daily after clinical signs were noted) by trained individuals for a period of 5 (Pilot) or 7 (Experiment 1) weeks to ensure mice were euthanized at a humane endpoint. In Experiment 1, 1 week before infection (i.e., baseline) and once each week for 7 weeks post-inoculation, mice underwent behavioral phenotyping in an open-field test in a sterile rat cage (18′′ × 8′′) divided into four quadrants located in a laminar flow hood. At 5- (Pilot) or 7-weeks (Experiment 1), the mice were sacrificed, and tissues were collected and stored for further analysis. Prior to humane euthanasia by CO2 overdose, fecal samples were collected, placed in TSB, frozen on dry ice, and quickly moved to a −80 °C freezer until thawing for DNA extraction. After euthanasia, mice were weighed and blood was collected by cardiac puncture, immediately mixed with 0.1 mL of 3.8% citrate, spun down, and plasma stored at −80 °C for analysis of plasma antibodies. During necropsy, two veterinarians (a pathologist and a gastroenterologist) observed and recorded any gross pathology prior to the removal of the GI tract. For the Pilot and Experiment 1, the cecum and colon were harvested, cut in half, and the halves flash frozen or streaked on TSAB-CVA plates for cytokine analysis and quantification of C. jejuni in these compartments, respectively. In Experiment 1, the ileocecocolic junction was harvested, infiltrated with 10% neutral-buffered formalin (NBF), placed in a cassette, and further fixed in NBF for 20–24 h and stored in 60% ethanol until processed for histological analysis.

Bacterial DNA isolation from feces and 16S ribosomal RNA gene analysis

In the pilot experiment, DNA was extracted from fecal samples using the QIAamp DNA stool kit (QIAGEN) according to manufacturer’s instructions. DNA concentrations were determined using a NanoDrop ND-1000 spectrophotometer and concentrations normalized. The quantity of Clostridium group 1, Clostridium group 1, Bacteroidetes, and Enterobacteriaceae were measured using an IQTM5 Multicolor Real-Time PCR Detection System. In Experiment 1, DNA was extracted from fecal samples using bead beating and the FastDNA SPIN Kit for Soil (MP Biomedicals, LLC) according to manufacturer’s instructions. The resulting DNA samples were delivered to the Michigan State University Research Technology Support Facility for library preparation and 16S rRNA gene amplicon analysis. In all, 62 samples were submitted for sequencing, including 60 mouse samples, the original fecal slurry used for inoculation of founder mice, and a mock community (HM-782D, BEI) for estimation of sequencing error. The V4 region of the 16S rRNA gene was amplified using dual-indexed primers [48]. PCR products were normalized using an Invitrogen SequalPrep DNA Normalization plate and the normalized products pooled. After quality control and quantitation, the pool was loaded on a standard MiSeq v2 flow cell and sequenced with a 500 cycle MiSeq v2 reagent kit (paired-end 250 base pair reads). Base calling was performed by Illumina Real-Time Analysis (RTA) v1.18.54 and output of RTA was de-multiplexed and converted to FastQ format files with Illumina Bcl2fastq v1.8.4.

16S rRNA gene amplicon analysis was performed using mothur (v. 1.35) and protocols available at accessed December, 2015. Alignment was achieved using the Silva 16S ribosomal gene database [49]. Chimeric sequences and any sequences classified as chloroplast, mitochondria, Archaea, or Eukaryota were removed from the dataset using uchime and the mothur formatted version of the Ribosomal Database Project (RDP) training set version 9, respectively, per the mothur protocol. Sequences were clustered in operational taxonomic units (OTUs) of 97% sequence identity yielding 128 OTUs. Analyses were performed in mothur and PAST 3.07 [50]. Sequence read data has been made available in the National Center for Biotechnology Information (NCBI) Sequence Read Archive (SRA) as documented in “Availability of data and materials.” A full record of the code used to develop the heat map that appears in Fig. 2, is based on the mothur protocol cited above. An annotated markdown file with the code for the heat map appears in Additional files 4 and 5.

Clinical signs assessments

We used a clinical sign score sheet developed to discern humane endpoints for gastrointestinal and neurological disease in mice; these have been approved by the MSU institutional animal care and use committee (IACUC) and published [30, 33, 35]. Briefly, mice were observed once a day by trained animal handlers and when clinical signs were discerned, they were documented and the mice were thereafter observed twice a day. A score sheet was filled out each time a mouse showed a clinical sign. Each sign has a point value and the scores for all signs observed were totaled for that observation period. If the score equaled or exceeded 9 then the mouse was humanely euthanized. Mice were assigned scores for a battery of clinical signs according to this scoring system: (1) Eating/Drinking (0 = yes, 1 = No); (2) Respiration (0 = normal, 1 = abnormal (increased), 10 = labored); (3) Rough hair coat (0 = no, 2 = yes), Hunched posture (0 = no, 9 = yes), Tremors (0 = no, 10 = yes), Movement (0 = normal, 1 = subdued (moves with stimulation), 2 = unresponsive to handling), Crusty eyes (0 = no, 1 = one eye, 2 = 2 eyes), Diarrhea on fur (0 = no, 1 = yes), Cool to the touch (0 = no, 10 = yes), and Body weight (0 = 0–1% weight loss, 1 = 1–5% weight loss). Endpoints resulting in a score greater than 9 include loss of body weight greater than 5%, cool to touch, blue extremities, or points adding up to greater than 9 in other criteria.

Quantification of C. jejuni in the cecum and colon

C. jejuni in the colon and cecum were quantified using a standardized semi-quantitative scoring system [30]. Briefly, colon and cecum tissue segments of the same size were collected at necropsy and were streaked on TSAB containing cefoperazone (2 μg/mL), vancomycin (10 μg/mL), and amphotericin B (2 μg/mL) (all antibiotics were obtained from Sigma-Aldrich, St. Louis MO) agar plates and grown in anaerobic jars equilibrated with CampyGen sachets (Oxoid) at 37 °C for 48–72 h. The resulting growth was assigned a score on a scale of 0–4 based on the density of growth; 0 (no growth), 1 (1–20 CFU), 2 (20–200 CFU), 3 (200–400 CFU), and 4 (confluent growth) as described [30].

Neurological phenotyping

Starting 1 week before experimental infections and then daily after inoculation with a C. jejuni strain, mice were observed daily for evidence of enteric and neurological disease. Daily monitoring was based on previously published clinical exam score sheets designed to score feature of gastrointestinal and neurological signs [30, 33]. Additionally, open-field testing was performed to detect neurological signs and changes in behavior due to inoculation with either GBS-associated or enteric-associated strains of C. jejuni. All TSB sham-inoculated control mice served as controls for phenotyping. The activity of all experimental mice was video-recorded once per week for 1 week before inoculation and once per week for 7 weeks post-inoculation. Briefly, mice were placed in the center of an 18′′ × 8′′ sterile rat cage divided into four marked quadrants and allowed to move freely for 90 s. At the completion of the experiment, a single investigator (PTB), who was blinded to mouse group identity, recorded the number of quadrants crossed and the number of rears for each mouse. Quadrants crossed were counted starting with the first line crossed after establishing all four limbs in a single quadrant. Rears were counted as the extension of hind limbs and placement of both front limbs on the side of the cage.

Scoring of ileocecocolic junction histopathology

Tissue samples were collected at necropsy, placed in cassettes, fixed in 10% NBF (Fisher Scientific) for 20–24 h, and then transferred to 60% ethanol until final processing. Samples were submitted to the Michigan State University Investigative Histopathology Laboratory where they were processed in the following manner: fixed samples were vacuum-infiltrated with paraffin on the Sakura VIP 2000 tissue processor; followed by embedding with a ThermoFisher HistoCentre III embedding station. Paraffin-embedded blocks were sectioned at 4–5 μm with a rotary microtome, dried at 56 °C in a slide incubator for 2–24 h, and stained with Hematoxylin and Eosin (H&E). Scoring of the distal ileum, cecum, and proximal colon was performed as described [30]. Briefly, the lumen, epithelium, lamina propria, and submucosa of the ileocecocolic junction (ICCJ) of each mouse were observed for histopathological changes by a single investigator (LSM) blinded to sample identity, and a score from 1 to 41 was assigned based on lesions using a standardized scoring system. Specific features evaluated among others were as follows: (1) excess mucus and inflammatory exudates in the lumen; (2) surface integrity, intraepithelial lymphocyte number, goblet cell hypertrophy, goblet cell depletion, crypt hyperplasia, crypt atrophy, crypt adenomatous changes, and crypt inflammation in the epithelium; (3) increased immune cells in the lamina propria; (4) and fibrosis in the submucosa.

Cytokine analysis

RNA was extracted from proximal colon samples that were flash frozen at the time of necropsy. Equal sized 5-mm-cubed tissue snips were homogenized using micropestles, and RNA was extracted following the RNeasy Plus Mini Kit protocol (QIAGEN). RNA concentrations were measured using the Nanodrop ND-1000 spectrophotometer and standardized to a concentration of 50 ng/μL. cDNA was obtained by PCR with random primers. A master mix was assembled using reagents from Promega GoTaq qPCR kit and added to the samples. This reaction was run using the following thermal cycler conditions: step 1, 5 min 25 °C; step 2, 20 min 42 °C; step 3, 70 °C; and step 4, 4 °C min—Hold. Interleukin 4 (IL-4) and Interferon gamma (IFNγ) cytokine levels were measured using qPCR on an iQ5 thermocycler (Bio-Rad) with standardization. ANOVAs were performed on 2-ΔΔct data to find the linear fold change in gene expression and are presented as mean fold change of three replicates over levels of the housekeeping gene hypoxanthine-guanine phosphoribosyltransferase (HPRT).

Enzyme-linked immunosorbent assays

Indirect enzyme-linked immunosorbent assays (ELISAs) were performed to test for the presence of antibodies reactive with bulk C. jejuni antigen and/or gangliosides GM1, GD1a, and GQb1 in the plasma of experimental mice, referred to as anti-Campylobacter and anti-ganglioside antibodies, respectively. Preparation of the bulk C. jejuni antigen was performed as previously described [30, 35]. Positive controls (highly reactive plasma samples that tested strongly for the presence of the antigen in previous experiments) and negative controls (monoclonal mouse anti-Toxoplasma gondii, ViroStat) were used in all cases. All samples were run in triplicate and the mean values used for statistical analysis. We tested for antibodies to gangliosides GM1 (Sigma), GD1a (USBio), and mixed GM1-GQ1b (Sigma, Calbiochem, respectively) [33]. Immunoglobulin (IgG) subtypes were determined using biotinylated goat anti-mouse-IgG1, IgG2b, IgG2c, and IgG3 (Jackson ImmunoResearch, West Grove, PA) secondary antibodies. Methods for C. jejuni-specific antibody ELISAs were described previously [30] and ganglioside ELISAs were conducted similarly [33].

Quantification of F4/80 positive cells in sciatic nerves and dorsal root ganglia

Sciatic nerves and 2–3 lumbar dorsal root ganglia (DRG) from L3, L4, and L5 were dissected, isolated, and fixed in 10% formalin pH 7.0. After that, tissues were embedded en bloc in order to assess the segmental nature of any GBS lesions [33]. Slides were prepared by the Michigan State University Investigative Histopathology Laboratory. Briefly, 3–5 μm sections were placed on charged slides, dried at 56 °C for approximately 12 h, and subsequently deparaffinized in xylene and hydrated through descending grades of ethyl alcohol to distilled water. Slides were placed in Tris-buffered saline (TBS) pH 7.4 (Scytek Labs—Logan, UT) for 5 min for pH adjustment. Following TBS, epitope retrieval was performed using Citrate Plus Retrieval Solution pH 6.0 (Scytek) in a vegetable steamer for 30 min followed by a 10-min countertop incubation and several changes of distilled water. Following pretreatment standard, avidin-biotin complex staining steps were performed at room temperature on the DAKO Autostainer. All staining steps are followed by 2-min rinses in Tris-buffered saline and Tween 20 (Scytek). After blocking with Normal Rabbit Serum (Vector Labs—Burlingame, CA) for 30 min, sections were incubated with avidin-biotin blocking system for 15 min each (Avidin D—Vector Labs/d-Biotin—Sigma). Primary antibody slides were incubated for 60 min with the Monoclonal Rat anti-Mouse F4/80 diluted at 1:100 (AbD Serotec—Raleigh, NC) in normal antibody diluent (NAD) (Scytek). Reaction development utilized Vector Nova Red Kit peroxidase chromogen incubation of 15 min followed by counterstaining in Gill’s Hematoxylin (Cancer Diagnostics—Durham, NC) for 30 s, differentiated with 1% acetic acid, dehydrated, and mounted with Permount (Sigma). F4/80 stained cells were counted and normalized for tissue area using ImageJ version 2.0.0-rc43/1.50e [51].

Statistical analysis

Statistical analyses were performed using GraphPad Prism 6.0 h for Mac OS X (GraphPad Software, La Jolla, California USA) with the exception of 16S rRNA gene amplicon analysis. Data were entered and then checked for normality and equal variance. If they passed both tests, one-way ANOVA was performed. If they failed either test, a Kruskal-Wallis test was performed instead, followed by Dunn’s post-test, with P < 0.05 constituting significance. Statistical analysis of histopathological scoring of ICCJ was performed using a Kruskal-Wallis test followed by Dunn’s post-test. Statistically significant comparisons in histopathology were further analyzed using Fisher’s exact test ( and corrected for multiple comparisons with the Holm-Sidak step-down procedure [30]. Two-way repeated measures ANOVA and Tukey’s post-test were used for analysis of open-field and rearing behavior in Experiment 1. Analysis of 16S rRNA gene amplicon data was performed using PAST 3 [50]; statistical procedures are indicated in figure legends.

For comparison of anti-ganglioside antibody levels between experimental groups, all datasets had unequal variances by one-way ANOVA so Kruskal-Wallis test was used in PAST. If the full table had a significant P in the Kruskal-Wallis test, pairwise tests between groups were conducted using the Mann-Whitney test; P values were adjusted for multiple comparisons using the Bonferroni procedure.



Conventional microbiota


Dorsal root ganglia


Enzyme-linked immunosorbent assays


Guillain Barré syndrome


Hematoxylin and eosin


Hypoxanthine-guanine phosphoribosyl transferase


Human microbiota


Ileocecocolic junction


Immunoglobulin G




Nicotinamide adenine dinucleotide


Neutral-buffered formalin


Operational taxonomic units


Post infection


Specific pathogen free


Tris-buffered saline


T helper 1


T helper 2


Tryptose soy broth


  1. 1.

    Mathis D, Benoist C. Microbiota and autoimmune disease: the hosted self. Cell Host Microbe. 2011;10(4):297–301.

  2. 2.

    Chervonsky AV. Microbiota and autoimmunity. Cold Spring Harb Perspect Biol. 2013;5(3):a007294.

  3. 3.

    Rosenblum MD, Remedios KA, Abbas AK. Mechanisms of human autoimmunity. J Clin Invest. 2015;125(6):2228–33.

  4. 4.

    Buffie CG, Pamer EG. Microbiota-mediated colonization resistance against intestinal pathogens. Nat Rev Immunol. 2013;13(11):790–801.

  5. 5.

    Kamada N, Chen GY, Inohara N, Nunez G. Control of pathogens and pathobionts by the gut microbiota. Nat Immunol. 2013;14(7):685–90.

  6. 6.

    Mathew CG. New links to the pathogenesis of Crohn disease provided by genome-wide association scans. Nat Rev Genet. 2008;9(1):9–14.

  7. 7.

    Wen L, Ley RE, Volchkov PY, Stranges PB, Avanesyan L, Stonebraker AC, Hu C, Wong FS, Szot GL, Bluestone JA, et al. Innate immunity and intestinal microbiota in the development of type 1 diabetes. Nature. 2008;455(7216):1109–13.

  8. 8.

    Pender MP. Preventing and curing multiple sclerosis by controlling Epstein-Barr virus infection. Autoimmun Rev. 2009;8(7):563–8.

  9. 9.

    Westall FC. Molecular mimicry revisited: gut bacteria and multiple sclerosis. J Clin Microbiol. 2006;44(6):2099–104.

  10. 10.

    Rodríguez-Reyna TS, Martínez-Reyes C, Yamamoto-Furusho JK. Rheumatic manifestations of inflammatory bowel disease. World J Gastroenterol. 2009;15(44):5517–24.

  11. 11.

    Toivanen P. Normal intestinal microbiota in the aetiopathogenesis of rheumatoid arthritis. Ann Rheum Dis. 2003;62(9):807–11.

  12. 12.

    van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014;10(8):469–82.

  13. 13.

    Koga M, Gilbert M, Li J, Koike S, Takahashi M, Furukawa K, Hirata K, Yuki N. Antecedent infections in Fisher syndrome: a common pathogenesis of molecular mimicry. Neurology. 2005;64(9):1605–11.

  14. 14.

    Nardelli DT, Callister SM, Schell RF. Lyme arthritis: current concepts and a change in paradigm. Clin Vaccine Immunol. 2008;15(1):21–34.

  15. 15.

    Ercolini AM, Miller SD. The role of infections in autoimmune disease. Clin Exp Immunol. 2009;155(1):1–15.

  16. 16.

    Sfriso P, Ghirardello A, Botsios C, Tonon M, Zen M, Bassi N, Bassetto F, Doria A. Infections and autoimmunity: the multifaceted relationship. J Leukoc Biol. 2010;87(3):385–95.

  17. 17.

    Blank M, Barzilai O, Shoenfeld Y. Molecular mimicry and auto-immunity. Clin Rev Allergy Immunol. 2007;32(1):111–8.

  18. 18.

    Cusick MF, Libbey JE, Fujinami RS. Molecular mimicry as a mechanism of autoimmune disease. Clin Rev Allergy Immunol. 2012;42(1):102–11.

  19. 19.

    Islam Z, Jacobs BC, van Belkum A, Mohammad QD, Islam MB, Herbrink P, Diorditsa S, Luby SP, Talukder KA, Endtz HP. Axonal variant of Guillain-Barre syndrome associated with Campylobacter infection in Bangladesh. Neurology. 2010;74(7):581–7.

  20. 20.

    Rees JH, Soudain SE, Gregson NA, Hughes RA. Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med. 1995;333(21):1374–9.

  21. 21.

    Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016;388(10045):717-27.

  22. 22.

    Yuki N. Guillain-Barré syndrome and anti-ganglioside antibodies: a clinician-scientist’s journey. Proc Jpn Acad Ser B Phys Biol Sci. 2012;88(7):299–326.

  23. 23.

    Pamela AO, Curt D, Mohamed KF, Catherine ML. Prevalence of the Campylobacter multi-drug efflux pump (CmeABC) in Campylobacter spp. Isolated from freshly processed Turkeys. Food Microbiol. 2006;23(5):453–60.

  24. 24.

    Chang C1, Miller JF. Campylobacter jejuni colonization of mice with limited enteric flora. Infect Immun. 2006;74(9):5261-71.

  25. 25.

    Stahl M, Ries J, Vermeulen J, Yang H, Sham HP, Crowley SM, Badayeva Y, Turvey SE, Gaynor EC, Li X, et al. A novel mouse model of Campylobacter jejuni gastroenteritis reveals key pro-inflammatory and tissue protective roles for toll-like receptor signaling during infection. PLoS Pathog. 2014;10(7):e1004264.

  26. 26.

    O’Loughlin JL, Samuelson DR, Braundmeier-Fleming AG, White BA, Haldorson GJ, Stone JB, Lessmann JJ, Eucker TP, Konkel ME. The intestinal microbiota influences Campylobacter jejuni colonization and extraintestinal dissemination in mice. Appl Environ Microbiol. 2015;81(14):4642–50.

  27. 27.

    Hughes RA, Cornblath DR. Guillain-Barre syndrome. Lancet. 2005;366(9497):1653–66.

  28. 28.

    Jacobs BC, Rothbarth PH, van der Meche FG, Herbrink P, Schmitz PI, de Klerk MA, van Doorn PA. The spectrum of antecedent infections in Guillain-Barre syndrome: a case-control study. Neurology. 1998;51(4):1110–5.

  29. 29.

    Shui IM, Rett MD, Weintraub E, Marcy M, Amato AA, Sheikh SI, Ho D, Lee GM, Yih WK, Team VSDR. Guillain-Barré syndrome incidence in a large United States cohort (2000-2009). Neuroepidemiology. 2012;39(2):109–15.

  30. 30.

    Mansfield LS, Bell JA, Wilson DL, Murphy AJ, Elsheikha HM, Rathinam VA, Fierro BR, Linz JE, Young VB. C57BL/6 and congenic interleukin-10-deficient mice can serve as models of Campylobacter jejuni colonization and enteritis. Infect Immun. 2007;75(3):1099–115.

  31. 31.

    Malik A, Sharma D, St Charles J, Dybas LA, Mansfield LS. Contrasting immune responses mediate Campylobacter jejuni-induced colitis and autoimmunity. Mucosal Immunol. 2014;7(4):802–17.

  32. 32.

    Bell JA, St Charles JL, Murphy AJ, Rathinam VA, Plovanich-Jones AE, Stanley EL, Wolf JE, Gettings JR, Whittam TS, Mansfield LS. Multiple factors interact to produce responses resembling spectrum of human disease in Campylobacter jejuni infected C57BL/6 IL-10-/- mice. BMC Microbiol. 2009;9:57.

  33. 33.

    St. Charles JL, Bell JA, Gadsden BJ, Malik A, Cooke H, Van de Grift LK, Kim HY, Smith EJ, Mansfield LS. Guillain Barré Syndrome is induced in Non-Obese Diabetic (NOD) mice following Campylobacter jejuni infection and is exacerbated by antibiotics. J Autoimmun. 2017;77(February 2017):11–38.

  34. 34.

    Young KT, Davis LM, Dirita VJ. Campylobacter jejuni: molecular biology and pathogenesis. Nat Rev Microbiol. 2007;5(9):665–79.

  35. 35.

    Mansfield LS, Patterson JS, Fierro BR, Murphy AJ, Rathinam VA, Kopper JJ, Barbu NI, Onifade TJ, Bell JA. Genetic background of IL-10(-/-) mice alters host-pathogen interactions with Campylobacter jejuni and influences disease phenotype. Microb Pathog. 2008;45(4):241–57.

  36. 36.

    Neal-McKinney JM, Lu X, Duong T, Larson CL, Call DR, Shah DH, Konkel ME. Production of organic acids by probiotic lactobacilli can be used to reduce pathogen load in poultry. PLoS ONE. 2012;7(9):e43928.

  37. 37.

    Tatem KS, Quinn JL, Phadke A, Yu Q, Gordish-Dressman H, Nagaraju K. Behavioral and locomotor measurements using an open field activity monitoring system for skeletal muscle diseases. J Vis Exp. 2014;91:51785.

  38. 38.

    Prut L, Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol. 2003;463(1-3):3–33.

  39. 39.

    Walsh RN, Cummins RA. The Open-Field Test: a critical review. Psychol Bull. 1976;83(3):482–504.

  40. 40.

    Griffin JW, Li CY, Macko C, Ho TW, Hsieh ST, Xue P, Wang FA, Cornblath DR, McKhann GM, Asbury AK. Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barré syndrome. J Neurocytol. 1996;25(1):33–51.

  41. 41.

    Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci. 2012;13(10):701–12.

  42. 42.

    Dinan TG, Cryan JF. Regulation of the stress response by the gut microbiota: Implications for psychoneuroendocrinology. Psychoneuroendocrinology. 2012;37(9):1369–78.

  43. 43.

    Cryan JF, Dinan TG. More than a gut feeling: the microbiota regulates neurodevelopment and behavior. Neuropsychopharmacology. 2015;40(1):241–2.

  44. 44.

    Mohan V. The role of probiotics in the inhibition of Campylobacter jejuni colonization and virulence attenuation. Eur J Clin Microbiol Infect Dis. 2015;34(8):1503–13.

  45. 45.

    Collins J, Auchtung JM, Schaefer L, Eaton KA, Britton RA. Humanized microbiota mice as a model of recurrent Clostridium difficile disease. Microbiome. 2015;3:35.

  46. 46.

    Wilson DL, Abner SR, Newman TC, Mansfield LS, Linz JE. Identification of ciprofloxacin-resistant Campylobacter jejuni by use of a fluorogenic PCR assay. J Clin Microbiol. 2000;38(11):3971–8.

  47. 47.

    Semchenko EA, Day CJ, Moutin M, Wilson JC, Tiralongo J, Korolik V. Structural heterogeneity of terminal glycans in Campylobacter jejuni lipooligosaccharides. PLoS ONE. 2012;7(7):e40920.

  48. 48.

    Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD. Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform. Appl Environ Microbiol. 2013;79(17):5112–20.

  49. 49.

    Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, Peplies J, Glockner FO. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res. 2013;41(Database issue):D590–6.

  50. 50.

    Hammer O, Harper DAT, Ryan PD. PAST: Paleontological statistics software package for education and data analysis. Palaeontol Electron. 2001;4:9.

  51. 51.

    Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9(7):671–5.

Download references


The authors would like to thank Leslie Dybas, Ankit Malik, Jessica St. Charles, and Alex Ethridge for their help in planning and carrying out the project, as well as providing insight during the data analysis.


These studies were funded in whole with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. N01-AI-30058 and Grant No. U19AI090872 Enterics Research Investigational Network, Cooperative Research Center. Support for the author K. A. Brakel was provided by the AVMA/AVMF 2nd Opportunity Research Grant. Research salary for Phillip T. Brooks were supported by the Institute for Integrative Toxicology at Michigan State University and a National Institutes of Environmental Health Sciences, NIH, Department of Health and Human Services grant number T35RR017491 to Michigan State University. Research salary for Trey Gilpin was funded through the Summer Research Opportunities Program (SROP) at Michigan State University.

Availability of data and materials

Illumina 16S amplicon sequence data that support the findings in this study were deposited in the National Center for Biotechnology Information (NCBI) Sequence Read Archive (SRA) under Bioproject accession number PRJNA380673 and Biosamples accession numbers SAMN06624816-SAMN06624875. Additionally, the OTU table (Additional file 6) and the Taxonomic assignments (Additional file 7) have been provided in CSV files.

Authors’ contributions

LSM, JAB, PTB, and KAB developed the experimental design, and directed and conducted the experiments with assistance from the group. This work constituted a chapter of the doctoral thesis for Phillip T. Brooks. KAB was involved in conduct and analysis of a significant body of the data and should be considered a co-first author on the manuscript. PTB conducted the 16s rDNA sequencing, data processing, and bioinformatic analyses. JAB prepared the C. jejuni inocula, cultured C. jejuni from mouse tissues, scored the culture results, assisted on the day of necropsy, oversaw the statistical analyses, and made critical comments on the manuscript. JMB and CEB conducted the delicate nerve dissections along with PTB to speed the process. JMB and LSM trained the others to conduct the nerve dissections. LSM gained funding for the projects and mentored PTB for his thesis work. LSM oversaw the development of the experimental design, gavaged the mice with C. jejuni, assisted with clinical monitoring of the mice, performed necropsies, harvested blood and tissue from mice at necropsy, and conducted gastrointestinal and nerve dissections, embedment, and evaluation of gastrointestinal and nerve tissue sections. LSM also assisted in preparation of the manuscript. All authors contributed to critical revisions and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approvals

All procedures involving animals were performed in accordance with the recommendations described in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health under protocols approved by the Michigan State University Institutional Animal Use and Care Committee (approval numbers 06/12-107-00 and 06/15-101-00).

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author information



Corresponding author

Correspondence to Linda S. Mansfield.

Additional files

Additional file 1: Figure S1.

Handling techniques do not alter abundance of select OTUs. (PPTX 151 kb)

Additional file 2: Table S1.

Principle components analysis. (PDF 82 kb)

Additional file 3: Table S2.

Indicator groups. Assemblage of indicator OTUs detected using indicator from the mothur pipeline. (PDF 179 kb)

Additional file 4:

Python code used to generate heatmap for 60 most abundant OTUs in humanized and conventional mice. OTUs were sorted, the 60 most abundant OTUs retrieved, and those OTUs clustered according to relative abundance using python (v 3.5) and seaborn (version 0.7.1). OTU abundance increases from light green to dark green. Left y-axis labels (network_pal) corresponds to the microbiota or inoculum; Humanized =brown; Conventional = bluegreen; inoculum = Teal. Right y-axis labels represent individual samples starting with group labels. Group labels; HI2= Humanized-Infected-260.94, HUT= Humanized-Uninfected-TSB, HI1= Humanized-Infected-11168, CI2= Conventional-Infected-260.94, CUT= Conventional-Uninfected-TSB, CI1= Conventional-Infected-11168, INO= Inoculum. (MD 4 kb)

Additional file 5:

SraRun Table. NCBI SRA sample submission report for bioproject PRJNA380673. (TXT 18 kb)

Additional file 6:

Relative abundances for all operational taxonomic units. Abundances of OTUs were determined using mothur. (CSV 41 kb)

Additional file 7:

Taxonomic assignments for all OTUs. Taxonomic assignments for OTUs in Additional file 3 determined using mothur. Reads were binned into OTUs using cluster.split and the average neighbor algorithm (cutoff=0.03). (CSV 20 kb)

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Brooks, P.T., Brakel, K.A., Bell, J.A. et al. Transplanted human fecal microbiota enhanced Guillain Barré syndrome autoantibody responses after Campylobacter jejuni infection in C57BL/6 mice. Microbiome 5, 92 (2017).

Download citation


  • Campylobacter jejuni
  • Guillain-Barré syndrome
  • Commensal microbiota
  • Mouse models
  • Autoimmunity
  • Gastrointestinal inflammation
  • Broad-spectrum antibiotics